奎思在阿尔茨海默病中的神经保护潜力:针对氧化应激,线粒体功能障碍和粉样β聚合
Mohd Adnan1,2, Arif Jamal Siddiqui1, Fevzi Bardakci1
1Department of Biology, College of Science, University of Ha'il, Ha'il, Saudi Arabia.
Frontiers in pharmacology
|June 26, 2025
概括
Quercetin 是一种天然的黄类化合物,通过减少粉样β (Aβ) 斑块形成和氧化应激,对阿尔茨海默病 (AD) 产生神经保护作用. 这种天然化合物对阿尔茨海默病的治疗具有前景.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 涉及粉样β (Aβ) 积累,氧化应激,线粒体功能障碍和胆固醇缺乏,导致神经退行.
- 这些病理特征有助于AD患者的神经元损伤和认知衰退.
研究的目的:
- 为了研究自然类黄胺 (flavonoid) - - 奎尔素在人类神经母细胞瘤SH-SY5Y细胞中对Aβ诱导的毒性的神经保护潜力.
- 评估奎尔素对细胞活力,氧化应激,线粒体功能,乙胆酶 (AChE) 活性和Aβ聚合的影响.
主要方法:
- 人类神经母细胞瘤SH-SY5Y细胞暴露于Aβ诱导的毒性.
- 进行了测试,以测量细胞活力,活性氧物种 (ROS) 水平,线粒体膜潜力 (ΔΨm),ACHE活性和Aβ聚合.
主要成果:
- 奎尔因通过降低细胞内ROS水平,显著改善了细胞活力并减少了氧化应激.
- 它保留了线粒体的完整性 (稳定 ΔΨm),抑制了 AChE 活性,并减少了 Aβ 聚合和有毒纤维素的形成.
结论:
- 奎尔素通过同时准多个AD病理途径来证明神经保护性质.
- 奎尔素显示出作为阿尔茨海默病的天然治疗剂的潜力,这需要进一步的体内和临床研究.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.一个Aβ聚合的Aβ聚合.在SH-SY5Y细胞中.粉样蛋白-β-β 的存在.神经保护神经保护氧化应激是一种氧化应激.文素 (Quercetin) 是一种文素.更多相关视频
06:23Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons
Published on: October 30, 2018
8.1K
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
12.1K
相关概念视频
01:22Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
01:26Alzheimer's Disease: Overview
684
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
684